LL-37

What it is (in plain language)
- Imagine LL-37 as a 'natural antibiotic' produced by the body itself. Not only does it directly destroy bacteria, fungi and viruses, it also acts as a signalling agent that recruits immune cells to the site of an infection. In addition, it has significant properties in healing chronic wounds and regulating skin inflammation.

Why do you appear online so much
- It is widely discussed in alternative health forums for the treatment of persistent infections (such as Lyme Disease or SIBO) and autoimmune skin conditions such as psoriasis. Its ability to modulate the inflammatory response makes it a compound of interest for those dealing with resistant bacterial biofilms.

How it is framed today (pragmatic view)
- 1) Evidence: Solid in microbiology and experimental dermatology. 2) Purpose: Fighting resistant pathogens and accelerating epithelial regeneration. 3) Risk: Due to its potent nature, use must be balanced to avoid an excessive immune response (cytokines).

How to use this form
- See the 'Mechanism' section to understand how LL-37 perforates bacterial membranes.

- Quick profile (curated by Subject 157)
- Class: Other
- Status: Verified
- Use case: Other
- Route: Injectable
- Tags: Injectable|Immune|Gut
- Half-life: Unknown
- Start: Fast
- Duration: Variable

- Mechanism (high level)
Antimicrobial peptide (cathelicidin). Destabilises pathogen membranes and modulates innate immune response (neutrophil chemotaxis).

- Evidence (what the literature covers)
RESEARCH RANGE (Non-prescriptive):
Low doses (100mcg) staggered.
Level of Evidence: C.

- Safety and harm-reduction (non-prescriptive)
Risks: Strong local inflammatory reaction (pain/redness).
Flu-like symptoms (die-off).
Interactions: Immunosuppressants.

- References (anchors)
- Heilborn, J. D. (2003) - LL-37 in wound healing and re-epithelialisation - https://doi.org/10.1046/j.1523-1747.2003.12069.x
- PubMed:12603850

Note: Educational/research content. Does not constitute medical advice, diagnosis or prescription.